Krystal K. Haase, Pharm.D., FCCP, BCPS
Reportable Conflicts of Interests: None
Disclosure of Financial Conflicts of Interest: None
Education:
Doctor of Pharmacy
The University of Texas at Austin College of Pharmacy
The University of Texas Health Science Center
Post Graduate or Residency Training:
The ACCP Leadership Experience
LeaderPoint
LLC Comprehensive Management Development Program
Mission, Kansas
ASHP/ACCP Accredited Specialty Residency in Pharmacotherapy Practice
Medical University of South Carolina
Charleston, SC
Fellowship and Board Certifications:
Fellow, American College of Clinical Pharmacy
Board Certified Pharmacotherapy Specialist
Advanced Cardiac Life Support
Basic Life Support
Current Position or Practice Site:
Associate Professor
Division of Adult Medicine
Department of Pharmacy Practice
Texas Tech School of Pharmacy
Amarillo, TX
Clinical Pharmacist
Critical Care and Adult Internal Medicine
Northwest Texas Hospital
Amarillo, TX
Relief Pharmacist
Amarillo Pharmaceutical Care Center
Texas Tech USHC School of Pharmacy
Amarillo, TX
Past Positions and/or Appointments:
Assistant Professor 1999-2006
Department of Pharmacy Practice
Texas Tech UHSC School of Pharmacy
Amarillo, TX
Professional Memberships:
American College of Clinical Pharmacy
American Association of Colleges of Pharmacy
American Society of Health System Pharmacists
Phi Lambda Sigma, Beta Pi Chapter, Texas Tech UHSC School of Pharmacy
American Society of Microbiology
Texas Society of Health System Pharmacists
Board of Pharmaceutical Specialties
Southwestern Residency Leadership Conference
Publications:
Haase KK, Smythe MA, Orlando PL, Resman-Targoff BH, Smith LS. ACCP Position Statement: Quality Experiential Education. American College of Clinical Pharmacy. Pharmacotherapy 2008;28:1548-51. Available at: http://www.accp.com/position/ExpEducPosStateFinal.pdf.
Haase KK, Smythe MA, Orlando PL, Resman-Targoff BH, Smith LS. ACCP White Paper: Quality Experiential Education. American College of Clinical Pharmacy. Pharmacotherapy 2008;28:1547. Available at: http://www.accp.com/position/ExpEducWPfinal.pdf.
Nappi JM, Haase KK, Kessels A, Fink J. What is a pharmacotherapy residency? Benefits of a 24 month program. Pharmacotherapy 2008;28:819-20.
Gallegos PJ, Maclaughlin EJ, Haase KK. Emerging use of brain natriuretic peptide for monitoring and titration of drug therapy in patients with heart failure. Pharmacotherapy 2008;28:343-55.
McCall KL, Raehl CL, Nelson S, Haase KK. Evaluation of blood pressure and heart rate reading accuracy as measured by students in the second professional year of a doctor of pharmacy program. Am J Pharm Educ 2007;71:Article 01.
Haase KK, McCracken KA, Akins RL. Catheter related bloodstream infections in the intensive care unit population. J Pharm Pract 2005;18;1:42-52.
Akins RL, Haase KK. Gram-positive resistance: pathogens, implications, and treatment options. Pharmacotherapy 2005;25:1001-10.
Akins RL, Haase KK. Gram-positive resistance: pathogens, implications and treatment options. Society of Infectious Diseases Pharmacotherapy Newsletter, 2004;14:2-7.
Roach AE, Tsikouris JP, Haase KK. Rosuvastatin: a new HMG-CoA reductase inhibitor for hypercholoesterolemia. Formulary 2002;37:179-185.
Cunningham AJ, Haase KK. Valdecoxib: A new COX-2 inhibitor. AJPM 2002;12:86-94.
Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Annals of Pharmacotherapy 2000;34:666-7.
Haase KK, Lapointe M, Haines SJ. Aseptic meningitis after intraventricular administration of gentamicin. Pharmacotherapy 2001;21:103-7.
Presentations (National, State and Local):
International & National
Converting Practice into Research: Developing the Clinician into an Investigator, 2005 Spring Practice and Research Forum, April 12, 2005. (moderator)
Collaborative Practices in the Inpatient Setting, Adult Medicine Focus Session at ACCP Annual Meeting, November 4, 2003. (moderator)
Comparison of Various Fluoroquinolones (FQs) and Four Other Antibiotics by Mutant Prevention Concentration (MPC) Against Multi-Drug Resistant Gram-Negatives Using Kill Curves Based on MPC-Derived Doses. Platform Presentation, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002.
Prevention of Radiocontrast-Induced Nephropathy. Internal Medicine Focus Session, Spring 2002 American College of Clinical Pharmacy Practice and Research Forum, Savannah, Georgia. April 2002.
How to Develop a Pharmacotherapy Specialty Residency. Round Table Presentation co-participant, American College of Clinical Pharmacy Annual Meeting, Phoenix, Arizona. November 1997.
State & Local Level
Optimal Control of Hyperglycemia in all Settings: Hyperglycemia in the ICU Patient. Panhandle Society of Health System Pharmacists, Amarillo, Texas. September 2007.
“Management of Hyperglycemia in the Critically Ill Patient.” West Texas Symposium: Successful Management of Hyperglycemia from Hospital to Home. Internal Cultural Center, Lubbock, Texas. November 2006.
Time Management Strategies for Leaders: A collection of thoughts from busy faculty. TTUHSC Residency Program Discussion Series, Amarillo, Lubbock, and Dallas, Texas. October 2006, August 2007.
Current Concepts in the Management of Hyperglycemia in the Critically Ill Patient. TTUHSC School of Pharmacy, Amarillo, Texas. May 2006; Baylor Hospital, Dallas, Texas. May 2006; North Texas VA Medical Center, Dallas, Texas. May 2006; West Texas VA Medical Center, Big Springs Texas. May 2006; Hendricks Health System, Abilene, Texas. July 2006.
Using Technology in Practice: Tablet PC’s. TTUHSC Convocation Hour, Spring 2006.
Residency Training: A Survival Guide for Students. TTUHSC Convocation Hour, September 2004.
“You’re Here, Now What?” Getting the Most from your Residency Year. TTUHSC Residency Workshop, Amarillo, Texas. July 2004.
Postdoctoral Training Opportunities for Pharmacists. Double T Society of Health System Pharmacists, Amarillo Texas. October 2001.
Emerging Strategies in the Treatment of Fluconazole-Resistant Candida. Continuing Pharmacy Education, Medical University of South Carolina, Charleston, South Carolina. November 1998.
Evaluation of the Treatment of Systemic Fungal Infections in Pediatric Patients. Platform Presentation, Southeastern Residency Conference, Augusta, Georgia. May 1998.
Glycoprotein IIb/IIIa Inhibitors: New antiplatelet agents in the treatment of acute coronary syndromes. Continuing Pharmacy Education, Medical University of South Carolina, Charleston, South Carolina. November 1997.
(Last updated: 2/9/2009)
